» Articles » PMID: 17898050

Plasma Cell-specific Transcription Factor XBP-1s Binds to and Transactivates the Epstein-Barr Virus BZLF1 Promoter

Overview
Journal J Virol
Date 2007 Sep 28
PMID 17898050
Citations 74
Authors
Affiliations
Soon will be listed here.
Abstract

Epstein-Barr virus (EBV) in vivo is known to establish persistent infection in resting, circulating memory B cells and to productively replicate in plasma cells. Until now, the molecular mechanism of how EBV switches from latency to lytic replication in vivo was not known. Here, we report that the plasma cell differentiation factor, XBP-1s, activates the expression of the master regulator of EBV lytic activation, BZLF1. Using reporter assays, we observed that XBP-1s was able to transactivate the BZLF1 promoter, Zp, in a plasma cell line and other lymphoid cell lines but, interestingly, not in epithelial cell lines. We have identified an XBP-1s binding site on the ZID/ZII region of Zp, which when abolished by site-directed mutagenesis led to abrogation of XBP-1s binding and promoter activation. Using the chromatin immunoprecipitation assay, we observed direct binding of XBP-1s to endogenous Zp in an EBV-infected plasma cell line. Finally, in the same cell line, we observed that overexpression of XBP-1s resulted in increased expression of BZLF1, while knockdown of XBP-1s with short hairpin RNA drastically reduces BZLF1 expression. We suggest that EBV harnesses the B-cell terminal differentiation pathway via XBP-1s as a physiological signal to reactivate and begin viral replication. We are currently investigating other signals, such as the endoplasmic reticulum stress response proteins, which act upstream of XBP-1s, to identify other interacting factors that initiate and/or amplify the lytic switch.

Citing Articles

Curcumin derivative C210 induces Epstein-Barr virus lytic cycle and inhibits virion production by disrupting Hsp90 function.

Chen L, Guo X, Lin W, Huang Y, Zhuang S, Li Q Sci Rep. 2024; 14(1):26694.

PMID: 39496752 PMC: 11535535. DOI: 10.1038/s41598-024-77294-w.


Epstein-Barr virus reactivation induces divergent abortive, reprogrammed, and host shutoff states by lytic progression.

SoRelle E, Haynes L, Willard K, Chang B, Chng J, Christofk H PLoS Pathog. 2024; 20(10):e1012341.

PMID: 39446925 PMC: 11563402. DOI: 10.1371/journal.ppat.1012341.


Epstein-Barr virus reactivation induces divergent abortive, reprogrammed, and host shutoff states by lytic progression.

SoRelle E, Haynes L, Willard K, Chang B, Chng J, Christofk H bioRxiv. 2024; .

PMID: 38915538 PMC: 11195279. DOI: 10.1101/2024.06.14.598975.


MicroRNA-focused CRISPR/Cas9 screen identifies miR-142 as a key regulator of Epstein-Barr virus reactivation.

Chen Y, Kincaid R, Bastin K, Fachko D, Skalsky R PLoS Pathog. 2024; 20(6):e1011970.

PMID: 38885264 PMC: 11213311. DOI: 10.1371/journal.ppat.1011970.


BCR signaling is required for posttransplant lymphoproliferative disease in immunodeficient mice receiving human B cells.

Zhang T, Cheng R, Ott A, Dahl N, Suchland E, Stoffers C Sci Transl Med. 2024; 16(742):eadh8846.

PMID: 38598616 PMC: 11493345. DOI: 10.1126/scitranslmed.adh8846.


References
1.
Schroder M, Kaufman R . The mammalian unfolded protein response. Annu Rev Biochem. 2005; 74:739-89. DOI: 10.1146/annurev.biochem.73.011303.074134. View

2.
Liou H, Boothby M, Finn P, DAVIDON R, Nabavi N, Zeleznik-Le N . A new member of the leucine zipper class of proteins that binds to the HLA DR alpha promoter. Science. 1990; 247(4950):1581-4. DOI: 10.1126/science.2321018. View

3.
Zheng Y, Gao B, Ye L, Kong L, Jing W, Yang X . Hepatitis C virus non-structural protein NS4B can modulate an unfolded protein response. J Microbiol. 2006; 43(6):529-36. View

4.
Huang J, Liao G, Chen H, Wu F, Hutt-Fletcher L, Hayward G . Contribution of C/EBP proteins to Epstein-Barr virus lytic gene expression and replication in epithelial cells. J Virol. 2006; 80(3):1098-109. PMC: 1346937. DOI: 10.1128/JVI.80.3.1098-1109.2006. View

5.
Cenci S, Mezghrani A, Cascio P, Bianchi G, Cerruti F, Fra A . Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO J. 2006; 25(5):1104-13. PMC: 1409720. DOI: 10.1038/sj.emboj.7601009. View